Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing…
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
“Eddington,” while not a comedy, presents an angry, sinister, and maybe crazy new America that it views with a deadpan tone of trepidatious glee. And…
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
This case-control of older US adults examines risk of Parkinson Disease by proximity of residence to a golf course.
Read our coverage of the major medical conferences that impact thoracic oncologists and surgeons.
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring…
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Immunotherapy for Urothelial Cancer: Types, Success Rate, Side Effects and More
